India bumps certifications to national level

Prompted by WHO concerns, Indian drug makers will begin approaching national regulatory authorities rather than state administrators to get facilities and export products certified. The switch, effective next month, is an attempt to streamline the regulatory process for pharmaceutical exports, but some expect it to add delays. Article

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.